Bluejay Diagnostics, Inc.BJDX
Price (close)
$0.92
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$7.3M
Dividend yield
—
1-year total return
-85.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Bluejay Diagnostics, Inc. does.
is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working
on developing rapid, near-patient tests using whole blood on our Symphony technology platform (“Symphony”), which consists
of an analyzer and single-use protein detection cartridges. We do not yet have regulatory clearance for Symphony, and we will need to
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $249,040 | — | — | — |
| Net income | -$1.2M | -$3.5M | -$9.3M | -$10.0M | -$7.7M | -$6.8M |
| Free cash flow | — | -$4.4M | -$8.9M | -$9.0M | -$8.1M | -$6.2M |
More on BJDX.
- Bluejay Diagnostics, Inc. summary
- Bluejay Diagnostics, Inc. financial statements
- Bluejay Diagnostics, Inc. key metrics
- Bluejay Diagnostics, Inc. health scores and style box
- Bluejay Diagnostics, Inc. earnings
- Bluejay Diagnostics, Inc. dividends
- Bluejay Diagnostics, Inc. valuation
- Bluejay Diagnostics, Inc. ownership and insiders
- Bluejay Diagnostics, Inc. peers
Figures from Bluejay Diagnostics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.